Aru Panwar, Swapnil Shah, Abigail E Reid, William Lydiatt, Andrew J Holcomb, Angela Osmolak, Andrew Coughlin, Oleg Militsakh, Yungpo B Su, Alireza Mirmiran, Tien-Shew Huang, Nicole Nolan, Randall Duckert, Christian Barney, Max Chiu, Cam Nguyen, Harlan Sayles, Apar Kishor Ganti, Robert Lindau
IMPORTANCE: Despite interest in therapy de-escalation for survivors of human papillomavirus-mediated oropharyngeal squamous cell carcinoma (HPV-positive OPSCC), the association of de-escalated therapy with patient-reported quality of life (QoL) outcomes and burden of depressive symptoms remains unclear. OBJECTIVE: To identify associations between clinicopathologic and therapeutic variables with patient-reported QoL outcomes and depression symptom burden in patients with HPV-positive OPSCC, who were enrolled in a therapy de-escalation trial...
April 4, 2024: JAMA Otolaryngology—Head & Neck Surgery